Anti-tumor drugs have become a large-scale and fast-growing therapeutic field
in the world, including the Chinese pharmaceutical market.
Data show that in 2021, the global anti-tumor drug market sales will reach 187 billion US dollars, and the growth rate will be stable at more than 10%; In China, the sales of anti-tumor drugs market have also been comparable
to the size of the anti-infective drug market.
According to intranet data, in 2020, the sales of anti-tumor drugs market have exceeded 145.
8 billion yuan
.
In addition, data show that in 2021, the market sales of anti-tumor drugs in the hospital totaled more than 88.
5 billion yuan, an increase of 13% year-on-year, and it is also growing
steadily in 2022.
Among them, in the first half of 2022, anti-tumor drugs with higher sales in the hospital include bevacizumab injection, trastuzumab for injection, ositinib mesylate tablets, paclitaxel for injection (albumin-conjugated), goserelin acetate extended-release implant, etc
.
Among them, the sales of bevacizumab injection in the first half of 2022 were 3.
238 billion yuan
.
Approved enterprises include Roche, Fuhong Henlius, Dongyao Pharmaceutical, Beida Pharmaceutical, Biotech Biologics, Suzhou Shengdia Biologics, Dongboan Biologics, Cinda Biologics, Qilu Pharmaceuticals
.
It is reported that the drug was originally developed as Roche, and in December 2019, Qilu was approved to produce bevacizumab injection (trade name: Anda), which is the first domestic bevacizumab biosimilar
.
Trastuzumab for injection sales in the first half of 2022 were $2.
739 billion
.
Approved enterprises include Roche, Rongchang Biologics, and Henlius Fuhong
.
Trastuzumab antigen research from Roche, in 2017, trastuzumab with a 65% reduction in the medical insurance directory, each bottle from 21613 yuan to 7600 yuan, after entering the medical insurance directory, rapid release
.
Oxitinib mesylate tablets sold 2.
258 billion yuan
in the first half of 2022.
The approved enterprise is AstraZeneca
.
Data show that ositinib mesylate tablets are third-generation EGFR-TKI-targeted therapy drugs with first-line treatment indications
.
At present, only the original research in China has been approved to list this variety
.
In addition, injectable paclitaxel (albumin-conjugated) hospital sales in the first half of 2022 were 1.
965 billion yuan
.
Approved enterprises include CSPC Ouyi, Jiangsu Hengrui, Celgene Corporation, Qilu, Hainan Kelun, Zhejiang Haizheng Pharmaceutical
.
The drug was developed by Celgene to treat metastatic breast cancer that fails with combination chemotherapy or breast cancer that recurs within 6 months after adjuvant chemotherapy
.
Goserelin acetate sustained-release implant has hospital sales of 1.
708 billion yuan in the first half of 2022, and the approved enterprise is AstraZeneca, which is a first-line drug
for prostate cancer treatment.
It is understood that with the increase of cancer patients, in recent years, the sales of anti-tumor drugs in the Chinese drug market have been showing a steady growth trend
.
The industry said that with the improvement of China's drug research and development environment, a number of domestic cancer innovative drugs have also emerged
.
For example, in the 2022 Annual Conference of the European Society of Internal Oncology (ESMO) recently held in Paris, France, the research and development of anti-tumor drugs has been fruitful, and the ESMO network and the websites of various enterprises show that the 2022 ESMO Conference has more than 70 research drafts from more than 20 Chinese pharmaceutical companies, and local innovative clinical research has been widely recognized by
the international academic community.
Among them, from the perspective of the number of releases, Hengrui Pharmaceutical has 29 achievements and 8 kinds of products; BeiGene, China Biopharmaceutical, Corning Jereh Pharmaceutical, Cinda Biologics, Junshi Biologics also have 3-5 innovative R&D achievements
.
={"common":{"bdSnsKey":{},"bdText":"","bdMini":"1","bdMiniList":false,"bdPic":"","bdStyle":"0","bdSize":"32"},"share":{},"image":{"viewList":[" weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"],"viewText":"Share to:","viewSize:"24"},"selectShare":{" bdContainerClass":null,"bdSelectMiniList":["weixin","sqq","qzone","tsina","tqq","tsohu","tieba","renren","youdao","fx","ty","fbook","twi","copy","print"]}}; with(document)0[(getElementsByTagName('head')[0]|| body).
appendChild(createElement('script')).
src='http://bdimg.
share.
baidu.
com/static/api/js/share.
js?v=89860593.
js?cdnversion='+~(-new Date()/36e5)];
